Declining Stock and Decent Financials: Is The Market Wrong About Hologic, Inc. (NASDAQ:HOLX)?
Lumos Diagnostics Receives $400,000 in Milestone Payment From Hologic; Shares Up 3%
Lumos Diagnostics Holdings (ASX:LDX) received $400,000 in milestone payment from women's health company Hologic as part of a development agreement announced in January, according to a Wednesday filing
Hologic on Track for Lowest Close Since December 2023 -- Data Talk
Hologic, Inc. (HOLX) is currently at $71.25, down $0.18 or 0.25% --Would be lowest close since Dec. 27, 2023, when it closed at $70.94 --Currently down nine of the past 10 days --Currently down eig
Hologic, Inc. (HOLX) Is Attracting Investor Attention: Here Is What You Should Know
Investors in Hologic (NASDAQ:HOLX) Have Seen Favorable Returns of 53% Over the Past Five Years
When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Furthermore, you'd generally like to see the share price rise faster than the market. Unfortunat
HOLX Vs. EW: Which Stock Should Value Investors Buy Now?
Investors looking for stocks in the Medical - Instruments sector might want to consider either Hologic (HOLX) or Edwards Lifesciences (EW).
Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It
Slowing Rates Of Return At Hologic (NASDAQ:HOLX) Leave Little Room For Excitement
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Ideally, a business will show two trends; firstly a growing return on capital employed (ROCE) and secondly, an incre
Express News | Hologic Shares Trims Gain, Last up 0.6%; FDA Says Hologic, Inc. Recalls Biozorb Marker Due to Complications With Implanted Devices
Express News | FDA: FDA Identified Hologic's Recall of Biozorb Marker as a Class I Recall
Express News | Hologic Recalls BioZorb Marker Due To Complications With Implanted Devices
Express News | Hologic, Inc. Recalls Biozorb Marker Due To Reported Complications And Adverse Events With Implanted Devices - FDA
Hologic to Webcast Presentations at Upcoming Investor Conferences
MARLBOROUGH, Mass.--(BUSINESS WIRE)--$HOLX #holx--Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the following upcoming investor conferences: 2024 Leerink Partners Healt
Meditrina Welcomes Senior Vice President of Global Sales to Lead Expansion Efforts and Manage Rapid Growth
Hologic's (NASDAQ:HOLX) Soft Earnings Don't Show The Whole Picture
Shareholders appeared unconcerned with Hologic, Inc.'s (NASDAQ:HOLX) lackluster earnings report last week. We think that the softer headline numbers might be getting counterbalanced by some positive
Hologic Is Maintained at Buy by Argus Research
Hologic Is Maintained at Buy by Argus Research
Argus Adjusts Price Target on Hologic to $95 From $89
Hologic (HOLX) has an average rating of outperform and price targets ranging from $70 to $95, according to analysts polled by Capital IQ.
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Hologic (HOLX) and Arbutus Biopharma (ABUS)
A Dive Into Hologic (HOLX) International Revenue Trends and Forecasts
Here Is What to Know Beyond Why Hologic, Inc. (HOLX) Is a Trending Stock
No Data